This method is a promising treatment for patients with leptomeningeal dissemination of HER2-positive breast cancer, but it will be some time before it is applied in clinical practice because the study population is small, enrollment in the ongoing clinical trials is poor, and the safety has not been sufficiently reported. Here, ERBB2 is linked to breast cancer.